Brokerages Expect Supernus Pharmaceuticals, Inc. (SUPN) to Announce $0.25 EPS
Wall Street analysts expect that Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) will post earnings per share of $0.25 for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Supernus Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $0.28 and the lowest estimate coming in at $0.24. Supernus Pharmaceuticals posted earnings of $0.18 per share in the same quarter last year, which suggests a positive year over year growth rate of 38.9%. The company is scheduled to issue its next earnings report on Tuesday, August 1st.
According to Zacks, analysts expect that Supernus Pharmaceuticals will report full year earnings of $1.08 per share for the current financial year, with EPS estimates ranging from $0.89 to $1.50. For the next financial year, analysts anticipate that the company will post earnings of $1.63 per share, with EPS estimates ranging from $1.45 to $2.01. Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Supernus Pharmaceuticals.
Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Tuesday, May 9th. The specialty pharmaceutical company reported $0.19 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.22 by $0.03. The firm had revenue of $57.58 million for the quarter, compared to analyst estimates of $57.91 million. Supernus Pharmaceuticals had a return on equity of 31.79% and a net margin of 42.46%.
Several brokerages have recently commented on SUPN. Piper Jaffray Companies upgraded shares of Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $30.00 to $44.00 in a research report on Thursday, June 1st. Jefferies Group LLC boosted their target price on shares of Supernus Pharmaceuticals from $35.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, May 31st. Zacks Investment Research upgraded shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Saturday, March 4th. Cowen and Company boosted their target price on shares of Supernus Pharmaceuticals from $31.00 to $34.00 and gave the company an “outperform” rating in a research report on Thursday, May 11th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $31.00 target price on shares of Supernus Pharmaceuticals in a research report on Tuesday, March 7th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $33.43.
In related news, VP Padmanabh P. Bhatt sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, June 2nd. The shares were sold at an average price of $39.86, for a total transaction of $398,600.00. Following the completion of the transaction, the vice president now directly owns 27,500 shares in the company, valued at approximately $1,096,150. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Padmanabh P. Bhatt sold 11,806 shares of the company’s stock in a transaction that occurred on Monday, April 24th. The stock was sold at an average price of $32.59, for a total transaction of $384,757.54. Following the transaction, the vice president now owns 45,500 shares of the company’s stock, valued at $1,482,845. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 83,806 shares of company stock valued at $2,813,038. 6.70% of the stock is owned by corporate insiders.
Institutional investors have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. acquired a new position in shares of Supernus Pharmaceuticals during the first quarter valued at about $127,000. Pacad Investment Ltd. acquired a new position in shares of Supernus Pharmaceuticals during the fourth quarter valued at about $124,000. Fortaleza Asset Management Inc. acquired a new position in shares of Supernus Pharmaceuticals during the first quarter valued at about $160,000. State of Alaska Department of Revenue boosted its position in shares of Supernus Pharmaceuticals by 3.2% in the first quarter. State of Alaska Department of Revenue now owns 5,530 shares of the specialty pharmaceutical company’s stock valued at $173,000 after buying an additional 170 shares during the period. Finally, OppenheimerFunds Inc. acquired a new position in shares of Supernus Pharmaceuticals during the first quarter valued at about $205,000. Hedge funds and other institutional investors own 92.08% of the company’s stock.
Supernus Pharmaceuticals (NASDAQ:SUPN) traded up 3.26% during mid-day trading on Wednesday, hitting $42.75. 606,255 shares of the stock traded hands. The firm’s 50-day moving average price is $35.99 and its 200-day moving average price is $29.53. The firm has a market cap of $2.15 billion, a P/E ratio of 23.00 and a beta of 1.76. Supernus Pharmaceuticals has a 52 week low of $17.25 and a 52 week high of $42.85.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.